Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote Sells 4,387 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at $972,921.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $12.24 on Thursday. The company has a market capitalization of $936.24 million, a price-to-earnings ratio of -5.83 and a beta of 0.71. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $14.07. The stock has a fifty day simple moving average of $9.48 and a 200 day simple moving average of $7.92. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million during the quarter, compared to analyst estimates of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. Sell-side analysts expect that Travere Therapeutics, Inc. will post -3.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Barclays upped their target price on Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Guggenheim upgraded shares of Travere Therapeutics from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a report on Monday. Citigroup upped their price target on shares of Travere Therapeutics from $14.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Bank of America upped their price target on shares of Travere Therapeutics from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Finally, HC Wainwright upped their price target on shares of Travere Therapeutics from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Institutional Trading of Travere Therapeutics

Institutional investors have recently bought and sold shares of the company. EntryPoint Capital LLC bought a new stake in Travere Therapeutics during the first quarter valued at $32,000. DRW Securities LLC bought a new stake in Travere Therapeutics during the second quarter valued at $95,000. Forefront Analytics LLC boosted its position in Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after acquiring an additional 1,237 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Travere Therapeutics by 68.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock valued at $113,000 after acquiring an additional 5,962 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in Travere Therapeutics during the second quarter valued at $117,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.